A University of Glasgow team developed an app-controlled robotic platform that enables the automated chemical synthesis and purification of drugs by including software that converts written chemistry protocols into code that drives production. Manual chemical...

Eisai and Glenmark settled patent litigation relating to Eisai’s Banzel rufinamide for seizures. Under the settlement terms, Glenmark will be permitted to market a generic version of Banzel in the U.S. on May 30, 2022,...

FDA approved an sNDA from Eisai for Banzel rufinamide as an adjunct treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ages 1-4. Eisai markets the triazole derivative in the U.S. as Banzel and...

FDA accepted and granted Priority Review to an sNDA from Eisai for Banzel rufinamide as an adjunct treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ages 1-3 years. The PDUFA date is Feb....

Eisai Co. Ltd. (Tokyo:4523) said FDA accepted for filing and granted Priority Review to an NDA for lenvatinib ( E7080 ) and an sNDA for rufinamide ( E2080 ). Eisai is seeking approval of lenvatinib to treat progressive,...

On Jan. 2, Eisai said it would launch Fycompa perampanel in the U.S. on Jan. 6 as adjunct treatment for partial onset seizures in patients with epilepsy ages 12 years and older. The wholesale acquisition...

Eisai launched NerBloc botulinum toxin type B intramuscular injection 2,500 unit in Japan to treat cervical dystonia. Each vial has a National Health Insurance (NHI) list price of ¥28,902 ($307). In 2000, Eisai received Japanese...

Eisai launched Inovelon rufinamide oral suspension in Spain for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients four years of age and older. Eisai markets the triazole derivative in the U.S....

Eisai submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for rufinamide as an adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome (LGS). Eisai markets the triazole derivative for patients >4...

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for rufinamide as an adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome (LGS). Eisai markets the triazole...